{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T05:13:37Z","timestamp":1778303617942,"version":"3.51.4"},"reference-count":36,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017239","name":"BeiGene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2023,1,28]]},"DOI":"10.1080\/10428194.2022.2150820","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T16:31:14Z","timestamp":1670517074000},"page":"329-338","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["A phase 1, open-label, randomized drug\u2013drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies"],"prefix":"10.1080","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1409-9489","authenticated-orcid":false,"given":"Bilal","family":"Tariq","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, BeiGene USA, Inc","place":["Fulton, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying C.","family":"Ou","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, BeiGene USA, Inc","place":["San Mateo, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer C.","family":"Stern","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, BeiGene USA, Inc","place":["San Mateo, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaibhav","family":"Mundra","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, BeiGene USA, Inc","place":["San Mateo, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Wong Doo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Concord Repatriation General Hospital","place":["Concord, Australia"]},{"name":"Concord Clinical School, University of Sydney","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peninsula Health and Peninsula Private Hospitals","place":["Frankston, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine L.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Haematology, Sir Charles Gairdner Hospital and Linear Clinical Research","place":["Nedlands, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chester","family":"Lin","sequence":"additional","affiliation":[{"name":"Biostatistics, BeiGene, Ltd","place":["Emeryville, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Novotny","sequence":"additional","affiliation":[{"name":"Clinical Development, Hematology, BeiGene USA, Inc","place":["San Mateo, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikumar","family":"Sahasranaman","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, BeiGene USA, Inc","place":["San Mateo, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-6458","authenticated-orcid":false,"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[{"name":"Clinical Hematology, Monash Health and Monash University","place":["Clayton, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2013.09.001"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3487"},{"key":"e_1_3_5_4_1","unstructured":"Brukinsa (zanubrutinib) [package insert]. San Mateo CA: BeiGene USA Inc.; 2021; Available from: https:\/\/www.brukinsa.com\/prescribing-information.pdf. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/213217s005lbl.pdf"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.832.832"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00687"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71182-9"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.02.008"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0163"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"e_1_3_5_17_1","unstructured":"Hillmen P Eichhorst B Brown JR et al. Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol. 2022;JCO2200510."},{"key":"e_1_3_5_18_1","unstructured":"Imbruvica (ibrutinib) [package insert]. South San Francisco CA: Pharmacyclics LLC; 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/205552s030 210563s006lbl.pdf."},{"key":"e_1_3_5_19_1","unstructured":"Calquence (acalabrutinib) [package insert]. Wilmington DE: AstraZeneca Pharmaceuticals LP; 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210259s006s007lbl.pdf"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/598327"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.156"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-04015-w"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12102"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2012.0128"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24826"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.4.642"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.125559"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90146-1"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00632-7"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1929961"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12605"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.128"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12619"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12948"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005621"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7521"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2022.2150820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:28:28Z","timestamp":1757924908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2022.2150820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1,28]]}},"alternative-id":["10.1080\/10428194.2022.2150820"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2022.2150820","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-08-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}